Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 13 | 2024 | 694 | 4.310 |
Why?
|
| Vaccination | 13 | 2024 | 635 | 2.220 |
Why?
|
| Wounds, Gunshot | 2 | 2024 | 19 | 1.830 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2023 | 19 | 1.780 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 155 | 1.480 |
Why?
|
| Humans | 53 | 2024 | 17611 | 1.370 |
Why?
|
| Male | 39 | 2024 | 10008 | 1.330 |
Why?
|
| Vaccines | 6 | 2022 | 212 | 1.320 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2017 | 59 | 1.310 |
Why?
|
| California | 22 | 2024 | 2284 | 1.300 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2022 | 531 | 1.290 |
Why?
|
| Electronic Health Records | 5 | 2024 | 681 | 1.280 |
Why?
|
| Adult | 28 | 2024 | 7598 | 1.260 |
Why?
|
| Managed Care Programs | 6 | 2017 | 325 | 1.130 |
Why?
|
| Adolescent | 21 | 2024 | 3651 | 1.110 |
Why?
|
| Firearms | 2 | 2024 | 32 | 1.100 |
Why?
|
| Female | 39 | 2024 | 12608 | 1.080 |
Why?
|
| Papillomavirus Vaccines | 6 | 2022 | 113 | 1.050 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 5 | 2017 | 32 | 1.040 |
Why?
|
| Opioid-Related Disorders | 4 | 2022 | 167 | 1.020 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2447 | 1.010 |
Why?
|
| Middle Aged | 24 | 2024 | 7911 | 1.000 |
Why?
|
| Machine Learning | 1 | 2024 | 46 | 0.930 |
Why?
|
| Community Health Centers | 1 | 2024 | 64 | 0.920 |
Why?
|
| Vaccination Coverage | 1 | 2024 | 41 | 0.900 |
Why?
|
| Chronic Pain | 2 | 2022 | 127 | 0.900 |
Why?
|
| Chickenpox Vaccine | 3 | 2015 | 91 | 0.860 |
Why?
|
| Papillomavirus Infections | 6 | 2022 | 133 | 0.860 |
Why?
|
| Fractures, Bone | 1 | 2023 | 91 | 0.850 |
Why?
|
| Young Adult | 16 | 2024 | 2427 | 0.830 |
Why?
|
| Immunization, Secondary | 3 | 2016 | 55 | 0.810 |
Why?
|
| Chickenpox | 2 | 2012 | 35 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 171 | 0.760 |
Why?
|
| Herpes Zoster | 4 | 2016 | 82 | 0.740 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 100 | 0.740 |
Why?
|
| Cohort Studies | 16 | 2023 | 2570 | 0.730 |
Why?
|
| United States | 14 | 2024 | 3956 | 0.660 |
Why?
|
| Aged | 14 | 2024 | 6095 | 0.650 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2019 | 93 | 0.640 |
Why?
|
| Hypertension | 1 | 2023 | 500 | 0.640 |
Why?
|
| Electronics, Medical | 1 | 2018 | 3 | 0.610 |
Why?
|
| Medicare Part D | 1 | 2017 | 15 | 0.580 |
Why?
|
| Cost Sharing | 1 | 2017 | 30 | 0.570 |
Why?
|
| Coinfection | 2 | 2019 | 30 | 0.560 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 107 | 0.550 |
Why?
|
| Influenza Vaccines | 4 | 2019 | 267 | 0.490 |
Why?
|
| Viral Load | 3 | 2021 | 135 | 0.480 |
Why?
|
| Primary Health Care | 4 | 2021 | 766 | 0.480 |
Why?
|
| Child | 13 | 2022 | 2474 | 0.470 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2015 | 382 | 0.470 |
Why?
|
| Tenofovir | 2 | 2023 | 18 | 0.450 |
Why?
|
| Hepatitis B | 1 | 2014 | 42 | 0.440 |
Why?
|
| Preventive Medicine | 1 | 2013 | 24 | 0.440 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 54 | 0.430 |
Why?
|
| Drug Utilization | 1 | 2013 | 127 | 0.430 |
Why?
|
| Incidence | 4 | 2023 | 1255 | 0.420 |
Why?
|
| Mothers | 1 | 2013 | 105 | 0.410 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 3 | 0.410 |
Why?
|
| Herpes Simplex | 1 | 2012 | 6 | 0.410 |
Why?
|
| Hospitalization | 4 | 2021 | 797 | 0.400 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 42 | 0.400 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 64 | 0.390 |
Why?
|
| Abortion, Spontaneous | 3 | 2021 | 47 | 0.380 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2022 | 178 | 0.380 |
Why?
|
| Databases, Factual | 1 | 2012 | 309 | 0.380 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 134 | 0.370 |
Why?
|
| Risk Assessment | 4 | 2024 | 1097 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 330 | 0.360 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 243 | 0.360 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1900 | 0.350 |
Why?
|
| Seizures, Febrile | 3 | 2015 | 42 | 0.350 |
Why?
|
| Buprenorphine | 2 | 2021 | 48 | 0.350 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 67 | 0.330 |
Why?
|
| Meningococcal Vaccines | 3 | 2022 | 39 | 0.330 |
Why?
|
| Child, Preschool | 7 | 2017 | 1409 | 0.320 |
Why?
|
| Age Factors | 4 | 2015 | 917 | 0.300 |
Why?
|
| Hepatitis C | 2 | 2021 | 65 | 0.290 |
Why?
|
| Risk Factors | 7 | 2022 | 3325 | 0.280 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2018 | 136 | 0.260 |
Why?
|
| Neoplasms | 2 | 2024 | 438 | 0.250 |
Why?
|
| Comorbidity | 3 | 2021 | 594 | 0.230 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 43 | 0.230 |
Why?
|
| Radiculopathy | 1 | 2023 | 5 | 0.230 |
Why?
|
| Fumarates | 1 | 2023 | 4 | 0.230 |
Why?
|
| Adenine | 1 | 2023 | 8 | 0.220 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 27 | 0.220 |
Why?
|
| Age Distribution | 1 | 2023 | 246 | 0.220 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.210 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 154 | 0.210 |
Why?
|
| Infant | 6 | 2018 | 1171 | 0.200 |
Why?
|
| Immunization Schedule | 2 | 2022 | 122 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 2 | 2015 | 147 | 0.200 |
Why?
|
| Premature Birth | 2 | 2021 | 137 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 151 | 0.190 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1322 | 0.190 |
Why?
|
| Vaccines, Combined | 2 | 2019 | 80 | 0.190 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2022 | 86 | 0.190 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 96 | 0.190 |
Why?
|
| Algorithms | 1 | 2022 | 233 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2020 | 33 | 0.170 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 25 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 415 | 0.170 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 3 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2020 | 31 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 13 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 34 | 0.160 |
Why?
|
| Risk | 2 | 2018 | 516 | 0.160 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 124 | 0.160 |
Why?
|
| Infant Mortality | 1 | 2018 | 20 | 0.150 |
Why?
|
| Odds Ratio | 3 | 2019 | 671 | 0.150 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 8 | 0.150 |
Why?
|
| Preconception Care | 1 | 2017 | 43 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 568 | 0.140 |
Why?
|
| Heart Failure | 1 | 2022 | 396 | 0.140 |
Why?
|
| Meningitis, Meningococcal | 1 | 2017 | 7 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 26 | 0.140 |
Why?
|
| Papillomaviridae | 1 | 2017 | 52 | 0.140 |
Why?
|
| Stroke | 1 | 2019 | 311 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.130 |
Why?
|
| Policy Making | 1 | 2016 | 15 | 0.130 |
Why?
|
| Time Factors | 3 | 2016 | 1086 | 0.130 |
Why?
|
| Prenatal Care | 1 | 2017 | 128 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 2015 | 1 | 0.130 |
Why?
|
| Ribavirin | 1 | 2015 | 8 | 0.130 |
Why?
|
| Poisson Distribution | 1 | 2015 | 88 | 0.130 |
Why?
|
| Alcoholism | 1 | 2019 | 347 | 0.130 |
Why?
|
| Mass Screening | 1 | 2021 | 661 | 0.130 |
Why?
|
| Sex Factors | 2 | 2015 | 643 | 0.130 |
Why?
|
| Hepacivirus | 1 | 2015 | 51 | 0.130 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2015 | 94 | 0.120 |
Why?
|
| African Americans | 2 | 2017 | 472 | 0.120 |
Why?
|
| Ethnic Groups | 3 | 2014 | 485 | 0.120 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2015 | 62 | 0.120 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 20 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 263 | 0.120 |
Why?
|
| Gonorrhea | 1 | 2014 | 18 | 0.120 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 25 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 59 | 0.110 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 417 | 0.110 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 23 | 0.110 |
Why?
|
| Logistic Models | 2 | 2015 | 926 | 0.110 |
Why?
|
| Quality Control | 1 | 2012 | 45 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 97 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2016 | 263 | 0.110 |
Why?
|
| Men's Health | 1 | 2012 | 20 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2012 | 21 | 0.100 |
Why?
|
| Vascular Calcification | 1 | 2012 | 9 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2021 | 844 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2014 | 298 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 351 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 120 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 205 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1115 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 21 | 0.090 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 44 | 0.090 |
Why?
|
| Smoking | 1 | 2013 | 483 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 710 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 709 | 0.080 |
Why?
|
| Stillbirth | 2 | 2021 | 29 | 0.080 |
Why?
|
| Pregnancy | 3 | 2021 | 1494 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 748 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 1309 | 0.070 |
Why?
|
| Seasons | 2 | 2019 | 102 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 884 | 0.070 |
Why?
|
| Cause of Death | 2 | 2018 | 181 | 0.070 |
Why?
|
| Headache | 1 | 2023 | 14 | 0.060 |
Why?
|
| Back Pain | 1 | 2023 | 33 | 0.060 |
Why?
|
| Prescriptions | 1 | 2023 | 27 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 1210 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 107 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2016 | 1259 | 0.050 |
Why?
|
| Naltrexone | 1 | 2020 | 17 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 10 | 0.040 |
Why?
|
| Appendicitis | 1 | 2019 | 15 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 24 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 50 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 181 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 202 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 25 | 0.040 |
Why?
|
| Congenital Abnormalities | 1 | 2017 | 26 | 0.040 |
Why?
|
| Vaccines, Conjugate | 1 | 2017 | 59 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 428 | 0.040 |
Why?
|
| Bell Palsy | 1 | 2017 | 14 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2020 | 280 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 14 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 154 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 110 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 55 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 35 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2015 | 54 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2015 | 64 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 260 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 114 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 227 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 5 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 95 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2017 | 404 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 18 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 529 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 77 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 163 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 297 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 111 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 358 | 0.030 |
Why?
|
| Minority Groups | 1 | 2013 | 101 | 0.030 |
Why?
|
| Calcitriol | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hypocalcemia | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hyperphosphatemia | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2010 | 2 | 0.020 |
Why?
|
| Ergocalciferols | 1 | 2010 | 3 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hypophosphatemia | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2010 | 12 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 7 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 11 | 0.020 |
Why?
|
| Minerals | 1 | 2010 | 9 | 0.020 |
Why?
|
| Calcinosis | 1 | 2010 | 40 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2010 | 74 | 0.020 |
Why?
|
| Vitamin D | 1 | 2010 | 76 | 0.020 |
Why?
|
Concepts
(230)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(46)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->